MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OTC: IGXT) , a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announced today that the Phase 1 Non-Binding LOI Submission Deadline set for 5:00 p.m. (EDT) on July 15, 2024 in connection with the previously announced sale and investment solicitation process (“ SISP... Read More

MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the extent to which different doses of Montelukast (MTK) could improve cognition in adults with AD as well as to... Read More

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “ Initial Order ”) under the Companies’ Creditors Arrangement Act (the “ CCAA ” and the “ CCAA Proceedings ”) by the Superior Court of Québec (the “ Court ”).... Read More

MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, was granted protection pursuant to an initial order (as amended, the “ Initial Order ”) issued under the Companies' Creditors Arrangement Act (“ CCAA ”)... Read More

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) - - IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announced today that its Board of Directors has authorized the Company and its subsidiary to bring an application in the Québec Superior Court (Commercial Division) (the “ Court ”) to seek... Read More

SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “ Company ” or “ IntelGenx ”) announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the “ Annual Meeting ”), shareholders voted in favour of all items of business put forth by the Company, including the election of the directors by a majority of the votes cast by shareholders... Read More

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm ® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that... Read More

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) - - IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for... Read More

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where... Read More

SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024. An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer and Andre Godin, President and Chief... Read More

SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “ Company ”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“ IntelGenx Corp. ”), has entered into a third amended and restated loan agreement dated as of March 8, 2024 (amending the second amended and restated loan agreement dated as of September 30, 2023) (the “ Loan Agreement ”) with atai Life... Read More

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.... Read More

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.... Read More

SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm ® platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the... Read More

SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”). Under the terms of the development agreement, Covenant Animal Health will fund development and... Read More

SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Company ”) announces the closing of the previously announced subsequent non-brokered private placement (the “ Subsequent atai Subscription ”) of 750 units (“ US Units ”) with atai Life Sciences AG (“ atai ”) for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023,... Read More

SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “ Company ” or “ IntelGenx ”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “ Board ”) effective December 2, 2023. Mr. Stegert and Dr. Rao were the Board designees for atai Life Sciences AG (“ atai ”) pursuant to the purchaser rights agreement by and... Read More

SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Company ”) is pleased to announce that, at its meeting held earlier today (the “ Special Meeting ”), the shareholders (the “ Shareholders ”) voted to approve all proposals related to financing transactions involving atai Life Sciences AG (“ atai ”) previously disclosed by the Company on August... Read More

SAINT LAURENT, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the Swedish Medical Products Agency (“MPA”), the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx’s Montelukast VersaFilm ® for the treatment of Parkinson’s Disease (“PD”). PD is the... Read More

SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Company ”) wishes to remind its shareholders of record as of October 2, 2023 (the “ Shareholders ”) of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 (the “ Special Meeting ”) as a virtual meeting... Read More

SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.... Read More

SAINT LAURENT, Quebec, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray Brands Inc. (“Tilray”) have entered into a further amendment (the “Second Amendment”) to their November 2018 license, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm ® products, settling IntelGenx’s... Read More

SAINT LAURENT, Quebec, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer, Andre Godin, President and Chief Financial Officer,... Read More

SAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for RIZAFILM ®1 from its commercial partner in the United States, Gensco Pharma (“Gensco ® ”). The PO triggers an upfront order deposit payment. A pre-specified milestone payment to IntelGenx from Gensco ® is also payable upon... Read More

SAINT LAURENT, Quebec, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed with the U.S. Food and Drug Administration (“FDA” or the “Agency”) by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”).... Read More

SAINT LAURENT, Quebec, Aug. 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Company ”) announces the closing of the first tranche of a non-brokered private placement (the “ Offering ”) of units (“ Units ”) from atai Life Sciences AG (“ atai ”) for aggregate gross proceeds of approximately US$3 million, including US$750,000 to be received by the Company pursuant to the... Read More

SAINT LAURENT, Quebec, Aug. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.... Read More

SAINT LAURENT, Quebec, Aug. 10, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into a binding term sheet agreement for the packaging of a pharmaceutical oral film product that its undisclosed CDMO customer is planning to commercialize in the United States. IntelGenx will package (film in pouch) the product at its cGMP manufacturing facility... Read More

SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer, Andre Godin, President and Chief Financial Officer,... Read More

SAINT LAURENT, Quebec, Aug. 01, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm ® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design... Read More

SAINT LAURENT, Quebec, July 25, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate... Read More

SAINT-LAURENT, Quebec, July 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “ Company ” or “ IntelGenx ”) announces the resignation of Mr. J. Bernard (Bernie) Boudreau from the Board of Directors (the “Board”) of the Company effective today. Mr. Boudreau was a Director of the Company since 2006 and the Vice Chairman since 2014. He was also the Chair of the Corporate Governance and... Read More

SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “ Company ” or “ IntelGenx ”) announces that, at the annual meeting of shareholders of the Company held on May 9, 2023 (the “ Annual Meeting ”), shareholders voted in favour of all items of business put forth by the Company, including the election of the directors, by a majority of the votes cast by... Read More

SAINT LAURENT, Quebec, May 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it is executing on a plan focussed on near-term revenue generation. “There is no question in my mind that IntelGenx has great science, services, assets, and people," said Dwight Gorham, the Company’s recently appointed CEO. "However, there is also a clear gap between that and how... Read More

Provides opportunity to address market gap, catering to growing industry demand for reliable and efficient testing services SAINT LAURENT, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") a leading drug delivery company, is pleased to announce that it has received an amended Drug Establishment License (“DEL”) from Health Canada, allowing the Company to conduct... Read More

SAINT LAURENT, Quebec, May 11, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2023... Read More

SAINT LAURENT, Quebec, May 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023. An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chairman, Dwight Gorham, Chief Executive Officer, and Andre Godin, President... Read More

SAINT LAURENT, Quebec, April 27, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQX: IGXT) (the “ Company ” or “ IntelGenx ”) announces that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of warrants originally issued to Cantone Research Inc. on August 5, 2021 (the “ Broker Warrants ”). The 613,000 Broker Warrants are exercisable for shares of common stock... Read More

SAINT LAURENT, Quebec, April 27, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the submitted abbreviated new drug application (“ANDA”) for Buprenorphine... Read More

SAINT LAURENT, Quebec, April 17, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s RIZAFILM ® VersaFilm ® 505(b)(2) new drug application (NDA) for the treatment of acute migraine. 1 RIZAFILM ® (U.S. market name for RIZAPORT ® ) is a proprietary oral thin... Read More

SAINT LAURENT, Quebec, April 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team. Following the planned retirement of its founder and CEO, Horst G. Zerbe, PhD, the new executive leadership team is designed to support its continued global growth as a leading CDMO for oral films and transdermal products, and in... Read More

SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where... Read More

SAINT LAURENT, Quebec, March 24, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 29, 2023. An accompanying conference call will be hosted by Dr. Horst G. Zerbe,... Read More

SAINT LAURENT, Quebec, March 23, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023. An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President... Read More

SAINT LAURENT, Quebec, March 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “ Company ” or “ IntelGenx ”) announces the closing of an offering by way of private placement (the “ Offering ”) to certain investors in the United States of convertible notes due March 1, 2027 (the “ Notes ”) for aggregate gross proceeds of approximately US$760,000 (C$1,000,000). The Notes will bear interest... Read More

SAINT LAURENT, Quebec, March 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, will be participating in the 35th Annual ROTH Conference , being held March 12–14, 2023 at the Ritz-Carlton Hotel in Dana Point, California. IntelGenx’s President and CFO, Andre Godin, will participate in a fireside chat hosted by Jonathan Aschoff,... Read More

SAINT LAURENT, Quebec, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form.” This film formulation patent covers Loxapine oral film formulations... Read More

SAINT-LAURENT, Quebec, Feb. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced a research collaboration with Per Svenningsson, MD, PhD, of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate the use of IntelGenx’s Montelukast... Read More

SAINT LAURENT, Quebec, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, announced today that it has entered into an exclusive supply agreement (the “Agreement”) for RIZAPORT ® (the “Product”) with ARWAN Pharmaceuticals Industries Lebanon s.a.l. (“ARWAN”) in various countries in the Middle East and North Africa (“MENA”) region, including... Read More

SAINT LAURENT, Quebec, Jan. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) today announced that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx”), has received a fourth and final term loan tranche (the “Loan”) in the amount of U.S.$3 million pursuant to its amended and restated secured loan agreement with atai Life Sciences (“atai”). The obligations under the Loan... Read More